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BBB = blood–brain barrier; CNS = central nervous system; EAE = experimental autoimmune encephalomyelitis; IFN = interferon; ICAM = intercel-
lular adhesion molecule; IL = interleukin; MMP = matrix metalloproteinase; MS = multiple sclerosis; RA = rheumatoid arthritis; RANKL = receptor
activator of nuclear factor-κB ligand; TGF = transforming growth factor; Th = T-helper (cell); TIMP = tissue inhibitor of metalloproteinase; TNF =
tumour necrosis factor; VCAM = vascular cell adhesion molecule.
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Introduction
IFNs are a family of naturally secreted proteins with
immunomodulatory functions. They enhance the ability of
macrophages to destroy tumour cells, viruses and bacte-
ria. The IFNs are divided into two types. Type 1 IFNs com-
prise IFN-α and IFN-β [1], and type 2 IFNs consist of IFN-γ
alone. All type 1 IFNs probably originate from one
common ancestral gene and are secreted in humans [2].
Under normal physiological conditions, type 1 IFNs are
secreted endogenously by most human cells at low levels
[3]. IFN-γ has a structure different from that of IFN-α and
IFN-β, and acts through a unique receptor complex. IFN-β
and IFN-γ appear to have opposing effects. IFN-γ pro-
motes inflammatory responses whereas IFN-β has anti-
inflammatory properties. IFN-γ can stimulate the
production of chemokines, and is a powerful activator of
mononuclear phagocytes, increasing their ability to
destroy intracellular micro-organisms and tumour cells.
Therefore, recombinant IFN-γ has been used clinically for
the treatment of a variety of conditions, including chronic
lymphocytic leukaemia, Hodgkin’s disease and other
disorders. IFN-γ has also been tried in immune-mediated
diseases such as rheumatoid arthritis (RA) and multiple
sclerosis (MS). IFN-γ was used in a multicentre, random-
ized, double-blind trial in 197 patients with active RA [4],
which compared recombinant IFN-γ and placebo subcuta-
neously for a period of 24 weeks. However, it appeared to
have no more therapeutic value than placebo. In MS
patients, IFN-γ provoked disease exacerbation [5].
In contrast, IFN-β given to MS patients during clinical trials
has been shown to reduce the relapse rate, to decrease
disease activity on magnetic resonance imaging scans,
and to delay disability progression [6–10]. The exact
mechanism of action of IFN-β therapy is not precisely
known at present. However, it has been shown that IFN-β
downregulates the proinflammatory cytokines IL-1β and
tumour necrosis factor (TNF)-α in vitro, and it enhances
IL-10 and IL-1 receptor antagonist production [11–13].
Other possible effects of IFN-β treatment include the
following (Fig. 1) [14]: enhancement of T-cell cytotoxity;
regulation of antibody production; inhibition of T-cell prolif-
eration and migration; enhancement of IL-2 production by
Th1 cells; upregulation of transforming growth factor
(TGF)-β1 and TGF-β-receptor 2 expression on peripheral
blood mononuclear cells; downregulation of major histo-
compatibility complex class II expression on virus-infected
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cells and tumour cells; activation of natural killer cells;
downregulation of several adhesion molecules; and
enhancement of soluble adhesion molecules in serum.
Type 1 IFNs have also been found to be effective in
antiangiogenic therapy for tumours such as haeman-
giomas [15,16] and Kaposi’s sarcoma [17]. The systemic
administration of IFN-α and IFN-β can induce regression
of vascularized tumours through a mechanism associated
with endothelial cell damage, which leads to necrosis
[18,19]. Two pathways of angiogenesis have recently
been identified, based on their dependence on the related
but distinct integrins αvβ3 and  αvβ5. Basic fibroblast
growth factor enhanced angiogenesis is dependent on
integrin αvβ3, whereas vascular endothelial growth factor
enhanced angiogenesis requires αvβ5. IFN-β has been
shown to downregulate basic fibroblast growth factor at
mRNA and protein levels [20].
This antiangiogenic capacity of IFN-β may also be of rele-
vance for the treatment of RA. The importance of angio-
genesis in the maintenance of arthritis has been
demonstrated in studies in which angiogenesis inhibitors
were found to prevent onset of collagen-induced arthritis
in rodents, and significantly suppressed established
disease [21–23]. Furthermore, intra-articular administra-
tion of a cyclic peptide antagonist of αvβ3 in rabbits
resulted in inhibition of synovial angiogenesis, as well as a
reduction in joint swelling, synovial infiltrate and pannus
formation, in both early and well established arthritis [24].
Importantly, in that study the αvβ3 antagonist provided sig-
nificant protection against the development of cartilage
erosions.
The present review addresses the possible role of IFN-β in
immune-mediated diseases such as MS and RA.
Rationale for the use of IFN-β β in multiple
sclerosis
Because IFNs possess antiviral properties, the rationale for
the use of IFN-β in MS in the past was based on the belief
that viruses may play a role in causing MS, as well as trig-
gering relapses of disease. At present MS is considered
an autoimmune disease, associated with immune activity
directed against an antigen derived from the central
nervous system (CNS). It is known that macrophages,
which express major histocompatibility complex class II
molecules, present non-self antigens to T-cell receptors
on Th1 cells. These activated T cells increase the expres-
sion of adhesion molecules such as intercellular adhesion
molecule (ICAM)-1 and vascular cell adhesion molecule
(VCAM)-1 on blood–brain barrier (BBB) endothelial cells.
By this mechanism activated T-cells can cross the BBB.
The activated T cells then activate macrophages, which in
turn produce TNF-α, nitric oxide, free radicals and pro-
teases, causing myelin damage.
In experimental autoimmune encephalomyelitis (EAE; a
well known animal model of MS) demyelination is associ-
ated with a Th1 response (IFN-γ, IL-2 and TNF-α produc-
Figure 1
Overview of functions of IFN-β. IL-1RA, IL-1 receptor antagonist; MHC, major histocompatibility complex; MMP, matrix metalloproteinase; 
NK, natural killer (cell); TGF, transforming growth factor; TNF, tumour necrosis factor.348
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tion), whereas Th2 cytokines (e.g. IL-4 and IL-10) tend to
ameliorate the clinical signs of disease in mice and Lewis
rats [25]. In MS, autoimmune T-cell responses to myelin
antigens, particularly myelin basic protein, may contribute
to the inflammatory processes in the CNS [26]. IFN-β has
been shown to suppress myelin basic protein reactive T
cells, to enhance the production of anti-inflammatory IL-4
and IL-10, and to decrease TNF-α and IFN-γ production
[27–30]. Thus, IFN-β may induce immune deviation
toward the production of Th2 cytokines, which may con-
tribute to its therapeutic benefit in MS [27].
Extravasation of T cells across the BBB into the CNS is
considered a major event in the pathogenesis of MS and
EAE. In EAE, kinetic studies have demonstrated that
antigen-specific T cells migrate to the CNS early in the
immune response, which is followed by enhanced recruit-
ment of a large number of non-antigen-specific T cells that
traverse into the CNS parenchyma. The majority of these
T cells are in an activated state [31]. Adhesion molecules
on the BBB, such as ICAM-1 and VCAM-1, play important
roles and may enhance T-cell trafficking into the CNS. The
effect of IFN-β could be caused in part through affecting
these adhesion molecules.
In EAE, expression of ICAM-1 and VCAM-1 correlates
with disease phase, specifically upregulation during the
initial phase and decreased expression during disease
remission [32]. Calabresi et al. [33] found increased levels
of soluble VCAM-1 in the sera of MS patients, which cor-
related with a decrease in the number of contrast-enhanc-
ing lesions on magnetic resonance imaging during IFN-β
treatment. Because soluble VCAM-1 results from the
cleavage of its bound form, increased serum levels of
soluble VCAM-1 might reflect a decrease in VCAM-1
expression on endothelium in MS patients treated with
IFN-β. This suggests that IFN-β may downregulate expres-
sion of adhesion molecules on the BBB, which inhibits T-
cell trafficking into the CNS.
The effects of IFN-β on cytokine profile and cell trafficking
in the MS models and patients described above have stim-
ulated studies on its potential for treatment of RA patients.
Innovative treatment of rheumatoid arthritis
patients
RA is a chronic inflammatory disease that affects the syn-
ovial tissue in multiple joints. In most patients the disease
leads to joint destruction and disability. Inflammation in RA
is believed to be mediated by activation of T cells, leading
to activation of macrophages and fibroblast-like synovio-
cytes. The latter produce a variety of proinflammatory
cytokines, which results in proliferation of synovial tissue
associated with destruction of cartilage and bone. Tissue
destruction in RA is closely related to the production of
matrix metalloproteinases (MMPs) and other proteinases,
which are able to degrade collagen and proteoglycans.
Macrophages play a central role in the amplification of
stimulatory signals and tissue destruction. Macrophages
are found in the synovial lining layer, where they may be
involved in protection against infection. In RA they are acti-
vated and mediate inflammation by the production of
cytokines such as TNF-α, IL-1β, IL-6, IL-12, IL-15, IL-18,
platelet derived growth factor and TGF. These cytokines
activate fibroblast-like synoviocytes, which maintain
macrophage activation by secretion of granulocyte–
macrophage colony-stimulating factor, IL-8 and other
soluble mediators. Fibroblast-like synoviocytes and osteo-
clasts invade bone and cartilage, where chondrocytes are
activated to produce further proinflammatory cytokines. It
is believed that TNF-α is a key cytokine controlling the pro-
duction of other proinflammatory cytokines.
As a consequence various anticytokine therapies for RA
have been tried in the clinic. IL-1 and TNF-α are present in
relatively high amounts in synovial fluid and synovial tissue
of RA patients [34–36] and, as major contributors to the
inflammatory and destructive manifestations of RA, they
were the first cytokines to be targeted for treatment of RA.
Although the natural inhibitors of IL-1 and TNF-α, namely
IL-1 receptor antagonist and soluble TNF receptor, are
present in rheumatoid synovium, there might not be enough
to neutralize the proinflammatory actions of IL-1 and TNF-α.
There appears to be an imbalance between proinflamma-
tory and anti-inflammatory molecules in RA joints.
Following animal studies, two forms of TNF inhibitors have
been used in clinical trials in RA: anti-TNF-α antibodies
and soluble receptors, which bind with high affinity to TNF.
A multicentre, placebo-controlled, double-blind trial in 73
patients was performed in 1994 [37]. Patients were fol-
lowed over 4 weeks. A single infusion of TNF inhibitor
induced significant improvement in arthritis activity. All
other clinical trials performed with agents that block TNF-
α revealed significant improvement in arthritis and protec-
tion against joint destruction [38–42].
The efficacy of recombinant human IL-1 receptor antago-
nist in RA patients was investigated in a 6-month, placebo-
controlled, double-blind, randomized trial [43]. A group of
472 patients with active RA received daily, subcutaneous
injections of placebo or one of three doses of recombinant
human IL-1 receptor antagonist. After 6 months, the
patients who received the highest dose of the active treat-
ment exhibited significant clinical improvement, and X-ray
films from those patients showed fewer bone erosions as
compared with patients who received placebo.
Other therapeutic targets in RA include MMPs, to prevent
the destruction of cartilage and bone. Collagenase
(MMP-1), stromelysin-1 (MMP-3) and MMP-13 play impor-
tant roles in RA [44–46]. Normal fibroblasts produce very349
low levels of MMP-1 and MMP-3. However, levels
increase markedly in response to a variety of stimuli, such
as cytokines, crystals and phagocytosis of debris [44,47].
Increased amounts of MMPs are present in cartilage from
patients with RA, and the level of enzyme activity corre-
lates with the severity of the lesion. Similarly, synovial fluid
from patients with RA exhibits an increase in MMP levels
[48,49]. Natural inhibitors that are specific for MMPs exist;
they are produced locally by chondrocytes and fibroblast-
like synoviocytes, and are termed ‘tissue inhibitors of met-
alloproteinases’ (TIMPs). It is likely that joint destruction is
in part due to a local imbalance between activated MMPs
and TIMPs [44,50]. One study investigated intraperitoneal
administration of TIMP-1 in the collagen-induced arthritis
mouse model [51] and showed a significant reduction in
the severity of disease as compared with untreated control
animals. Several chemotherapeutic agents, antibiotics and
synthetic peptides can inhibit the activity of MMPs.
Despite promising preclinical data, MMP inhibitors have
not been used extensively in the clinic [46]. Minocycline –
an antibiotic that can inhibit MMP activity – has been eval-
uated in three well controlled trials in RA [52–54]. All trials
showed some improvement in the patient groups treated
with minocycline as compared with placebo.
IFN-β β therapy in animal models of
rheumatoid arthritis
An alternative approach could be administration of IFN-β
because IFN-β has been shown to downregulate the
proinflammatory cytokines IL-1β and TNF-α in vitro, while
possibly protecting against cartilage destruction by inhibi-
tion of IL-1β and MMP activity [55]. Increased production
of IL-10 and IL-1 receptor antagonist also suggests that
IFN-β therapy has potential as an antirheumatic strategy.
The effect of IFN-β in collagen-induced arthritis in mice
was investigated by means of IFN-β gene therapy [56].
Fibroblasts from DBA/1 mice were infected with a retro-
virus expressing murine IFN-β and were injected intraperi-
toneally into DBA/1 mice. This procedure has the
advantage of a constant level of expression of IFN-β by
syngeneic fibroblasts. Mice were injected with IFN-β-
expressing fibroblasts before the onset of arthritis, and
paw swelling, arthritic score and histological joint damage
were assessed. The animals injected with the IFN-β-
expressing fibroblasts developed less severe disease as
compared with the control group, and there was a signifi-
cant decrease in paw swelling.
The effect of treatment on established disease has also
been studied. A single intraperitoneal injection of IFN-β-
expressing fibroblasts was given in different dosages of
cells after the onset of arthritis, again with significant
improvement in clinical scores and decreased paw
swelling as compared with untreated animals [56]. Histol-
ogy revealed significant reductions in joint destruction in all
groups of mice treated with IFN-β, indicating that constitu-
tive expression of IFN-β has chondroprotective properties.
In the same study, total level of type II collagen specific IgG
and the levels of IgG1 and IgG2a were measured in order to
investigate the effects of IFN-β treatment on the immune
response to type II collagen. A modest decrease in total
anticollagen IgG levels was observed. Anticollagen IgG2a
(regarded as a marker for a Th1 response) was reduced,
and there was an increase in IgG1 (regarded as a marker
for a Th2 response). Taken together, an increase in the
IgG1:IgG2a ratio was observed, which may indicate a mod-
ulation of a Th1 to a Th2 immune response. Furthermore,
IFN-β could inhibit production of TNF-α, IL-12 and IFN-γ
production  in vitro in a dose-dependent manner. These
effects were reversed by anti-IFN-β antibodies, giving
further support to the hypothesis that IFN-β is able to
downregulate Th1 responses.
A study in which mice with collagen-induced arthritis
received daily intraperitoneal injections (up to
2.5 µg/mouse per day) of exogenous IFN-β yielded similar
results [57]. A significant decrease in inflammation and,
more importantly, a statistically significant decrease in car-
tilage and bone destruction were observed in the IFN-β
treated group as compared with control mice. Of impor-
tance, the protection of joint integrity appeared to be the
most important effect of IFN-β.
Consistent with these observations, Takayanagi et al. [58]
recently demonstrated the critical role of IFN-β in bone
homeostasis. Those investigators observed that mice
lacking IFN-β exhibited severe osteopenia, probably by
downregulating osteoclastogenesis. Bone-resorbing
osteoclasts and bone-forming osteoblasts are essential to
maintenance a balance between bone resorption and
bone formation. When this balance is disrupted in favour
of the osteoclasts, bone destruction (as observed in RA)
may follow. Osteoclast numbers and activity are depen-
dent on the balance between the osteoclast-promoting
receptor activator of nuclear factor-κB ligand (RANKL)
and osteoclast-inhibiting osteoprotegerin. In addition,
there is a negative feedback mechanism by which osteo-
clasts can control their own differentiation. RANKL
induces the expression of IFN-β in osteoclast precursor
cells via the transcription factor c-Fos (an essential tran-
scription factor for the formation of osteoclasts). IFN-β is
then released from these cells, and binds to and activates
its own cell surface receptor system on osteoclast precur-
sors, leading to a decrease in c-Fos levels. Lack of c-Fos
leads to inhibition of osteoclast differentiation [59]. Thus,
the IFN-β regulatory mechanism is important to mainte-
nance of bone homeostasis, supporting the view that IFN-
β therapy may be used to inhibit bone destruction [58,59].
In addition to studies conducted in mouse models, IFN-β
therapy has been evaluated in collagen-induced arthritis in
Available online http://arthritis-research.com/content/4/6/346350
rhesus monkeys [14]. The monkeys were susceptible to
collagen type II induced arthritis because of lack of the
major histocompatibility complex class I allele A-26. Three
out of four monkeys had active polyarthritis at the time of
treatment initiation. The fourth monkey was in a preclinical
phase of the disease, as shown by elevation in serum
acute phase reactants and synovial inflammation by
arthroscopy. The monkeys were treated with a high
dosage of 37 µg/kg mammalian cell-derived recombinant
IFN-β1a subcutaneously each day for 1 week. Two
monkeys with established arthritis exhibited clear clinical
improvement after treatment, and the monkey with preclini-
cal synovitis never developed signs of arthritis. During IFN-
β treatment all four monkeys had a marked decrease in
serum C-reactive protein levels. Thus, that study con-
firmed previous work in mouse collagen-induced arthritis
indicating that continous production of IFN-β by trans-
fected cells or daily IFN-β injections has potential as an
antirheumatic strategy.
IFN-β β therapy in patients with arthritis
The preclinical studies encouraged us to perform an open
phase I study in 12 patients with active RA [14]. They
were treated with IFN-β subcutaneously three times a
week, which is the schedule used in MS patients but
differs from the treatment schedule used in the collagen-
induced arthritis models described above. We chose not
to use daily injections because it was anticipated that this
would be less tolerable to the patients. Three different
doses of IFN-β were used: 22 µg, 44 µg and 66 µg. Treat-
ment was in general well tolerated. Although there was
gradual and significant improvement in tender joint count,
swollen joint count, patient’s assessment of pain, and
patient’s and doctor’s global assessment, the effects
appeared to be limited. Conceivably, the clinical effects
could have been more pronounced after treatment with
daily injections. It should be noted, however, that this
uncontrolled pilot study was not designed to demonstrate
a clinical effect.
Arthroscopy was performed in these patients and synovial
biopsies were taken before study entry, after 1 month and
after 3 months of IFN-β treatment [55]. A statistically sig-
nificant reduction in the mean immunohistological scores
for expression of IL-1β, IL-6, MMP-1 and TIMP was
observed in synovial tissue from RA patients after IFN-β
therapy, suggesting a biological effect of the treatment.
Another pilot study was recently performed [60]. Six chil-
dren with juvenile rheumatoid arthritis were treated for
16 weeks with weekly intramuscular injections of 10 or
20 µg/m2 IFN-β. All patients tolerated the treatment well
and all six patients met criteria for a 30% response after
treatment. Three of the six children even improved by at
least 50%. It should be stressed, however, that this study
was not placebo controlled.
There are two case reports claiming the development of
RA after the onset of IFN-β treatment. One report
describes a patient who developed a seropositive poly-
arthritis, which fulfilled the American Colllege of Rheuma-
tology criteria for RA, after 1.5 years of IFN-β treatment for
MS [61]. In that case it appears that IFN-β was at least
unable to prevent the onset of RA. Another case report
describes a patient with the HLA-DRB1*0404 allele who
developed a seronegative symmetric polyarthritis of the
wrists and hand joints after 8 weeks of IFN-β treatment for
MS [62]. Eight months after the IFN-β treatment ended,
symptoms of arthritis subsided, with resolution of the syn-
ovitis. That patient did not fulfill the American College of
Rheumatology criteria for RA. Taken together, these case
reports show that IFN-β therapy does not prevent the
development of arthritis in all patients.
Conclusion
In conclusion, IFN-β therapy has been shown to slow the
progression of disability in patients with relapsing-
remitting MS, and might also have antirheumatic poten-
tial. It remains to be shown whether these exciting
biological effects can translate into clinically meaningful
improvement if the cytokine is administered only three
times weekly or if more continous levels of IFN-β are
required.
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